Clinical trials: Diabetes Risk
Diabetes Mellitus, Type 1
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the…
- Trial name
- TN07 (NCT00419562)
- Testing
- Oral Insulin
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 560 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diet Modification, Substance Use Disorders
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
The purpose of this study is to test if a parenting program can be used to prevent substance use among Latino youth and at the same time promote healthy eating.
- Conditions
- Diet Modification, Substance Use Disorders, Diabetes Mellitus Risk, Cardiovascular Risk Factor
- Trial name
- FPNG+ (NCT03517111)
- Testing
- Nutrition/substance use prevention, Substance use prevention only, Academic success program
- Where
- United States
- Volunteers
- 844 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Renal Pelvis Cancer, Restless Legs Syndrome
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in the Adverse Events…
- Conditions
- Renal Pelvis Cancer, Restless Legs Syndrome, Epilepsy, Neuropathic Pain
- Trial name
- NCT01138124
- Testing
- Gabapentin prescriptions
- Volunteers
- 54,202 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes, Hypoglycemia
CGM Use in Poorly Controlled Youth With Type 1 Diabetes
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in high risk, poorly controlled pediatric Type 1 diabetes patients increases uptake of personal CGM use, and…
- Conditions
- Type 1 Diabetes, Hypoglycemia, High Blood Sugar
- Trial name
- IMPaCT (NCT04721145)
- Testing
- Dexcom G6 Continuous Glucose Monitor
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Johns Hopkins University
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cardiovascular Diseases, Cardiovascular Risk Factor
Cooking for Health Optimization With Patients
Cooking for Health Optimization with Patients (CHOP) is the first known multi-site prospective cohort study with a nested Bayesian adaptive randomized trial in the preventive cardiology field of culinary medicine.
- Conditions
- Cardiovascular Diseases, Cardiovascular Risk Factor, Nutrition Disorders, Diabetes
- Trial name
- CHOP (NCT03443635)
- Testing
- Treatment
- Where
- United States
- Volunteers
- 7,192 people, healthy volunteers welcome
- Sponsor
- Tulane University
Overweight and Obesity, PreDiabetes
Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation
The purpose of this research study is to determine whether continuous glucose monitors (CGM) are a safe, effective, and acceptable way to evaluate type 2 diabetes risk in youth as compared to the standard 2-hour oral glucose…
- Conditions
- Overweight and Obesity, PreDiabetes, Insulin Resistance
- Trial name
- NCT05404711
- Testing
- CGM
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mary Ellen Vajravelu, MD
Type 1 Diabetes
Group Visits for High Risk Type 1 Diabetes (T1D)
The investigators propose to conduct a pilot prospective cohort study to assess the impact of shared medical appointments (SMA) visits in underserved youth with poorly controlled type 1 diabetes (T1D).
- Trial name
- NCT05431686
- Testing
- SMA visits
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Children's National Research Institute
Diabetes Mellitus, Type 1
TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk
The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes.
- Trial name
- TRIGR (NCT00179777)
- Testing
- Hydrolysed infant formula, Nonhydrolysed infant formula
- Where
- 18 sites in United States, Australia and 13 more
- Volunteers
- 5,156 people
- Sponsor
- University of Helsinki
Cardiovascular Disease, Type 2 Diabetes
Complement and Cardiovascular Risk in Adolescents
This study evaluates how genetic variations in complement, a part of the immune system, affect cardiovascular risk in adolescents.
- Trial name
- CCRIA (NCT02821104)
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who…
- Trial name
- PREVENTKD (NCT00729365)
- Testing
- Ramipril
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Northwestern University
Type 1 Diabetes
Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)
The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1…
- Trial name
- NCT02580877
- Testing
- 67.5 mg oral insulin crystals daily, 500mg oral insulin crystals every other week
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 92 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the…
- Trial name
- NCT04270942
- Testing
- teplizumab 1 mg/mL
- Where
- 8 sites in United States
- Volunteers
- 6 people
- Sponsor
- Provention Bio, a Sanofi Company